News and Updates

Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020

Strategic Technologies for Europe Platform survey

Published on | 2 months ago

Programmes Digital, Industry & Space Agro-Food, Environment Digital Europe

The Strategic Technologies for Europe Platform (STEP) was set up by the EU to support the European industry and boost investment in critical technologies in Europe. STEP raises and steers funding across 11 EU programmes to three target investment areas:

  • Digital technologies and deep-tech innovation
  • Clean and resource-efficient technologies
  • Biotechnologies

STEP also supports projects growing the skills necessary to develop those critical technologies. STEP introduces a new STEP Seal – an EU label for high quality projects granting STEP projects visibility and facilitating their access to other possible sources of funding.

STEP is currently conducting a brief survey on access to EU funding. In case you are interested in contributing your point of view, you can access the survey here. The survey is open until 27 September 2024.

myOVERVIEW
- sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1484 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.